Bayer Pharma on the fast lane: Good news from Regorafenib
Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this analysis", said Kemal Malik, MD, Head of Global Development. The good news come three weeks after Bayer's Rivaroxaban reached an endpoint in its own Phase III study against acute coronary syndrome. Regorafenib significantly improved the overall survival of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. Bayer said this is the result of an interim analysis conducted by an independent Data Monitoring Committee (DMC) of the CORRECT (Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. The study has been unblinded and patients in the placebo arm will be offered treatment with regorafenib. Only days before the announcement Bayer had settled a legal dispute about the rights for Regorafenib and the cancer drug Nevaxar. Onyx Pharmaceuticals had claimed that a cooperation alliance with Bayer of the year 1994 resulted in rights for the compound Regorafenib.